Home Featured

Featured

Latest

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop

Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

EDITOR PICKS

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

What Lynn Watkins Actually Told the FDA about Chronic Pain and...

‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop

Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

EDITOR PICKS

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

What Lynn Watkins Actually Told the FDA about Chronic Pain and...

‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY